### AIDIAN



## QuikRead go® iFOBT

Quantitative testing in the best interest of the patient

# Quantitative testing in the best interest of the patient.

QuikRead go® iFOBT is a faecal immunochemical test (FIT) for detection and quantification of hemoglobin (Hb) in faeces. The test provides quantitative (numerical), instrument-read results in minutes.

Many people do not experience symptoms in the early stages of CRC. However, the blood vessels of colorectal polyps or cancers are often fragile and easily bleed into the colon or rectum. In healthy individuals, small quantities of lower gastrointestinal bleeding is normal, but it may also be a symptom of a gastrointestinal disorder. In symptomatic patients, point of care (POC) QuikRead go iFOBT provides quantitative information on excessive bleeding and aids in triaging patients for further gastrointestinal tract investigations, such as colonoscopy. FIT levels also correlate with the cancer severity.<sup>1,2</sup>



#### References

- Navarro M et al. Fecal hemoglobin concentration, a good predictor of risk of advanced colorectal neoplasia in symptomatic and asymptomatic Patients. Front Med (Lausanne) 2019; 6:31.
- Mclean W et al. Diagnostic accuracy of point of care faecal immunochemical testing using a portable high-speed quantitative analyser for diagnosis in 2-week wait patients. Colorectal Disease 2021: 00:1–11.
- European commission. European guidelines for quality assurance in colorectal cancer screening and diagnosis – First Edition. Segnan N, Patrick J, von Karsa L (eds.), 2010, Luxenboure.
- Rex D et al. Colorectal Cancer Screening: Recommendations for Physicians and Patients from the U.S. Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol 2017; 112:1016-1030.

## QuikRead go iFOBT is adjustable, fast and easy to use

- Quantitative results enable use of national recommendations
- Testing is close to the patient
- · Handy and hygienic sampling vial
- · Instrument-read results
- Results are automatically stored
- · Bi-directional connectivity to LIS/HIS

The early detection of CRC or its precursors significantly improves the chance for survival, requires less invasive treatment, and reduces treatment costs. Screening of people at moderate risk for CRC have been shown to reduce CRC mortality and incidence.<sup>3</sup>

Screening of CRC using FIT tests is recommended currently by the Council of Europe in the EU countries and by the American College of Physicians in the USA for individuals between 50–74 years old.<sup>3,4</sup>

#### Contact info

Aidian Oy

aidian@aidian.eu / +358 10 309 3000

For orders: orders@aidian.eu

Product	Cat. no
QuikRead go iFOBT, 50 tests	151051
QuikRead iFOB Sampling set, 50 devices	151052
QuikRead go iFOBT Control Quantitative	152390
QuikRead FOB Positive Control	06027
QuikRead go Instrument (FI, SE, NO, DK, CZ, SK, HU, PL)	135867
QuikRead go Instrument (UK)	149915
QuikRead go Instrument (Other Countries)	133893



aidian.eu